Plasma Proteomic Analysis Based on 4D-DIA Evaluates the Clinical Response to Imrecoxib in the Early Treatment of Osteoarthritis
Abstract Introduction Nonsteroidal anti-inflammatory drugs (NSAIDs) are the primary treatment for osteoarthritis (OA), but prolonged use has adverse effects and varying efficacy. Among NSAIDs, imrecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, reduces side effects yet remains ineffective for...
Main Authors: | Han Xie, Yuan Zhang, Zunyi Zhu, Jingxuan Wei, Gulinigeer Ainiwaer, Weihong Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2024-01-01
|
Series: | Rheumatology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40744-023-00636-z |
Similar Items
-
Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice
by: Yang Miao, et al.
Published: (2023-11-01) -
Towards Precision Medicine for Osteoarthritis: Focus on the Synovial Fluid Proteome
by: Lorenzo Moretti, et al.
Published: (2022-08-01) -
Serum proteomic panel validated for prediction of knee osteoarthritis progression
by: Virginia Byers Kraus, et al.
Published: (2024-03-01) -
Proteomic Analysis of Female Synovial Fluid to Identify Novel Biomarkers for Osteoarthritis
by: P. Robinson Muller, et al.
Published: (2023-02-01) -
Proteomic profiling of human menisci from mild joint degeneration and end-stage osteoarthritis versus healthy controls
by: Rocío Paz-González, et al.
Published: (2023-12-01)